Monday, July 20, 2009

What Does J&J’s Stake in Elan Say About Interest in Biogen?

J&J and Elan have “arrangements in place” relating to Tysabri, the multiple sclerosis drug Elan markets with Biogen.
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)